Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Looks To Resume Unannounced Inspections In India And China

13 Dec 2021

• By Shannon Brown

US FDA ramping up inspections in China and India • Source: Alamy

Related Content

India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections

21 May 2021

Real-Time Manufacturing Volume Reporting Could Help Prevent Drug Shortages, Woodcock Tells Congress

31 Oct 2019

US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule

27 Jan 2021

Senators Press For More Surprise Drug GMP Inspections Abroad

04 Jun 2020

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

07 Jul 2021

US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

01 Dec 2021

Confronting Illusions of Quality in Indian Generics Manufacturing

28 Mar 2014

Additional Topics

United States Manufacturing Quality Enforcement Compliance BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.